Choosing a GLP-1 with type 2 diabetes and weight to lose

If you have type 2 diabetes and weight to lose, a GLP-1 for type 2 diabetes and weight can tackle both at once — but the right choice depends on how you're currently being treated, whether the NHS is involved, and which medicine best fits your goals. This guide walks you through it, if-this-then-that style, and shows you what the private options actually cost.

GLP-1 for type 2 diabetes and weight: why one medicine does both

GLP-1 receptor agonists mimic a gut hormone that's released when you eat. They prompt the pancreas to release insulin when blood sugar is high, slow how quickly the stomach empties, and reduce appetite. The result is better blood sugar control and meaningful weight loss — which is why they've become central to type 2 diabetes care as well as weight management.

Tirzepatide (the active ingredient in Mounjaro) goes one step further: it acts on two hormone receptors, GLP-1 and GIP. In weight-loss trials of people without diabetes, that dual action produced average losses of around 21–22% at the higher doses. For someone carrying both a diabetes diagnosis and excess weight, that combined benefit is genuinely useful.

Start here: are you being treated on the NHS?

Your situation decides your route. Sort yourself into one of these groups.

• You have type 2 diabetes and see an NHS diabetes team. Talk to them first. GLP-1 medicines like semaglutide (Ozempic) are already prescribed on the NHS for diabetes control in appropriate cases, and Mounjaro is licensed for type 2 diabetes too. If a GLP-1 suits your diabetes care, you may not need to pay privately at all.
• Your diabetes is well managed but you still have weight to lose. A private weight-management service may be an option — but the prescriber must know exactly what diabetes medicines you already take.
• You take insulin or a sulfonylurea (e.g. gliclazide). Combining these with a GLP-1 can cause low blood sugar (hypoglycaemia). This isn't a reason to rule it out, but it does need a prescriber to adjust your other medicines — never something to manage alone.

Not sure which questions matter most? Our five questions that decide your GLP-1 shortlist is a good companion to this page.

Mounjaro or Wegovy when you have diabetes?

Both are strong choices, but they differ.

Mounjaro (tirzepatide) is licensed both for type 2 diabetes and, separately, for weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide produced around 20% weight loss versus about 14% for semaglutide. Its dual GLP-1/GIP action also gives it strong blood-sugar-lowering effects. For someone who wants maximum weight loss alongside diabetes, it's often the front-runner — see which GLP-1 gives maximum weight loss for the full picture.

Wegovy (semaglutide 2.4mg) delivered around 15% average weight loss in the STEP 1 trial. Semaglutide is very well established in diabetes (as Ozempic), so it's familiar territory for many diabetes teams.

If you're brand new to all of this, our Mounjaro or Wegovy for beginners guide covers the practical first steps. The key point for you specifically: whichever you choose, a prescriber needs your full diabetes history to judge suitability and adjust your other medicines.

What Mounjaro costs privately

If you go the private weight-management route, prices vary widely for the identical pen. Below is a sample of UK-regulated providers at the 2.5mg starter dose, with any first-order promo shown. Prices were checked 01 September 2026 — always confirm the current figure on the provider's own site, and see the full price table on our homepage.

Across all the providers we track, the 2.5mg starter dose ranges from £131 to £220 — an £89 spread for the same medicine. The cheapest headline price isn't always the best fit, though: for someone with diabetes, having a prescriber who takes your full picture seriously matters more than saving a few pounds.

Dosing and eligibility

Mounjaro is started low and increased slowly to reduce side effects: 2.5mg weekly for four weeks (a starter dose, not a treatment dose), then 5mg, then raised in 2.5mg steps after at least four weeks each, up to a maximum of 15mg. Your maintenance dose is tailored to you.

Privately, tirzepatide for weight is typically offered to adults with a BMI of 30+, or 27+ with a weight-related condition — and type 2 diabetes itself is a weight-related condition. If your BMI is in the 27–30 band, our BMI 27–30 options guide explains what's available. On the NHS, Mounjaro for weight (NICE TA1026) is being rolled out in phases from 2025, prioritising those with the highest BMI and most weight-related conditions first, so access still varies by area.

Side effects to know about

The most common side effects are nausea, diarrhoea, constipation, vomiting and tiredness — usually worst when you step up a dose and easing over time. Rarer but serious risks include pancreatitis, gallstones, and dehydration that can strain the kidneys. For people with diabetes specifically, the big one is low blood sugar when a GLP-1 is combined with insulin or a sulfonylurea — another reason your prescriber needs the full list of what you take.

Already on a GLP-1 and wondering about moving to tirzepatide? Our guide to switching between GLP-1 medications explains how that works.

FAQ